A5052712056- RNA Interference and Gene Delivery
- Nanoplatforms for cancer theranostics
- Immunotherapy and Immune Responses
- Advanced biosensing and bioanalysis techniques
- CAR-T cell therapy research
- Nanoparticle-Based Drug Delivery
- Ferroptosis and cancer prognosis
- Graphene and Nanomaterials Applications
- Immune cells in cancer
- CRISPR and Genetic Engineering
- Photodynamic Therapy Research Studies
- Cancer Research and Treatments
- Cancer, Lipids, and Metabolism
- Immune Cell Function and Interaction
- Cancer, Hypoxia, and Metabolism
- Dendrimers and Hyperbranched Polymers
- Cancer Cells and Metastasis
- Inflammasome and immune disorders
- Virus-based gene therapy research
- Immune Response and Inflammation
- Advanced Drug Delivery Systems
- Circular RNAs in diseases
- Antimicrobial agents and applications
- Metal-Organic Frameworks: Synthesis and Applications
- Kawasaki Disease and Coronary Complications
Jiangnan University
2023-2025
South China University of Technology
2019-2023
Guangzhou Medical University
2019-2020
Guangzhou First People's Hospital
2019-2020
Indiana University School of Medicine
2020
University of Science and Technology of China
2015-2018
Hefei University
2018
State Council of the People's Republic of China
2018
The CRISPR/Cas9 gene editing technology holds promise for the treatment of multiple diseases. However, inability to perform specific in targeted tissues and cells, which may cause off-target effects, is one critical bottlenecks therapeutic application CRISPR/Cas9. Herein, macrophage-specific promoter-driven Cas9 expression plasmids (pM458 pM330) were constructed encapsulated cationic lipid-assisted PEG-b-PLGA nanoparticles (CLAN). obtained encapsulating able specifically express macrophages...
The NLRP3 inflammasome is a well-studied target for the treatment of multiple inflammatory diseases, but how to promote current therapeutics remains large challenge. CRISPR/Cas9, as gene editing tool, allows direct ablation at genomic level. In this study, we screen an optimized cationic lipid-assisted nanoparticle (CLAN) deliver Cas9 mRNA (mCas9) and guide RNA (gRNA) into macrophages. By using CLAN encapsulating mCas9 gRNA-targeting (gNLRP3) (CLANmCas9/gNLRP3), disrupt macrophages,...
Cancer nanomedicine combined with immunotherapy has become a promising strategy for treating cancer in terms of safety and potency; however, precise regulation the activation antitumor immunity remains challenging. Herein, smart semiconducting polymer nano-immunomodulator (SPNI), which responds to acidic tumor microenvironment (TME), precision photodynamic cancer, is reported. The SPNI self-assembled by near-infrared (NIR)-absorbing an amphipathic conjugated Toll-like receptor 7 (TLR7)...
Ferroptosis is a form of iron-dependent, lipid peroxidation–driven regulatory cell death that has been implicated in the pathogenesis multiple diseases, including organ injury, ischemia/reperfusion, and neurodegenerative diseases. However, inhibitors directly specifically target ferroptosis are not yet available. Here, we identify compound AS-252424 (AS) as potent inhibitor through kinase library screening. Our results show AS effectively inhibits peroxidation both human mouse cells....
Schematic diagram showing that CLAN<sub>mRNA</sub> stimulates the maturation of DCs, promotes expansion antigen-specific T cells and induces robust anti-tumor immune response.
Treatment of chronic myeloid leukemia (CML) with cationic lipid-assisted polymeric nanoparticles (CLANs) carrying the CRISPR/Cas9 targeting BCR-ABL fusion gene.
Abstract Developing precise nanomedicines to improve the transport of anticancer drugs into tumor tissue and final action site remains a critical challenge. Here, we present bioorthogonal in situ assembly strategy for prolonged retention within areas act as drug depots. After extravasating site, slightly acidic microenvironment induces exposure cysteine on nanoparticle surface, which subsequently undergoes reaction with 2-cyanobenzothiazole group another neighboring nanoparticle, enabling...
Accumulating evidence has confirmed that malignant tumors have a complex microenvironment, which consists of heterogeneous collection tumor cells and other cell subsets (including the full gamut immune cells). Tumor-associated macrophages (TAMs), derived from circulating Ly6Chi monocytes, constitute most substantial fraction tumor-infiltrating in nearly all cancer types contribute to progression, vascularization, metastasis, immunosuppression, therapeutic resistance. Interrupting monocyte...
Lymph nodes (LNs) are normally the primary site of tumor metastasis, and effective delivery chemotherapeutics into LNs through systemic administration is critical for metastatic cancer treatment. Here, we uncovered that improved perfusion in a facilitates nanoparticle translocation to inhibiting metastasis. On basis our finding an iCluster platform, which undergoes size reduction from ∼100 nm ∼5 at site, markedly particle interstitium tumor, further revealed current study such tumor-specific...
Tumor-infiltrating dendritic cells (TIDCs) are mostly immature and immunosuppressive, usually mediating immune inhibition. The utilization of cytosine-guanine oligodeoxynucleotides (CpG ODNs) to stimulate the activation TIDCs has been demonstrated be effective for improving antitumor immunity. However, a series biological barriers limited efficacy previous nanocarriers delivering CpG TIDCs. Herein, we developed dual-sensitive dendrimer cluster-based nanoadjuvant ODNs into We show that tumor...
In recent years, small nanoparticles (NPs) with a diameter of less than 10 nm have aroused considerable interest in biomedical applications. However, their intratumor performance, as well the antitumor efficacy, has not been understood due to size-dependent pharmacokinetics, which presents formidable challenge for delivering comparable amount different NPs tumor tissues. Utilizing multistage delivery strategy, we construct G3-, G5-, and G7-iCluster systems by using poly(amidoamine) (PAMAM)...
Nanotechnology has shown great promise in treating diverse diseases. However, developing nanomedicines that can cure autoimmune diseases without causing systemic immunosuppression is still quite challenging. Herein, we propose an all-in-one nanomedicine comprising autoantigen peptide and CRISPR-Cas9 to restore specific immune tolerance by engineering dendritic cells (DCs) into a tolerogenic phenotype, which expand autoantigen-specific regulatory T (Treg) cells. In brief, utilized cationic...
Abstract Blocking immune checkpoint pathways with an antibody or small interfering RNA (siRNA) has become a promising method to reactivate antitumor responses for cancer treatment. However, both blockade strategies achieve only temporary inhibition of these checkpoints. Herein, photoswitched CRISPR/Cas9 system genomic disruption the PD‐L1 gene is developed permanent PD‐1/PD‐L1 pathway; this constructed by using photoactivated self‐degradable polyethyleneimine derivative and plasmid...
NLRP3 inflammasome-mediated immune responses are involved in the pathogenesis of multiple inflammatory diseases, but few clinical drugs identified that directly target inflammasome to treat these diseases date. Here, we show anticancer agent tivantinib is a selective inhibitor and has strong therapeutic effect on inflammasome-driven disease. Tivantinib specifically inhibits canonical non-canonical activation without affecting AIM2 NLRC4 activation. Mechanistically, by blocking ATPase...